Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions
NCT ID: NCT01021267
Last Updated: 2009-11-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2009-11-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Saw palmetto berry extract
Saw palmetto berry extract, organic saw palmetto, ethanolic extract 96%
Saw palmetto berry extract
1x daily 1 capsule containing 320mg lipophilic extract
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saw palmetto berry extract
1x daily 1 capsule containing 320mg lipophilic extract
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IPSS \> 4
* BSFI, sexual drive questions \< 5
Exclusion Criteria
* Patients with severe vascular disorders (microangiopathies)
* Patients with known neuropathies
* Severe diabetes mellitus
* Patients with hypertension who are for less than two months on a stable antihypertensive medication
* Known bad compliance of the patient
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of London
OTHER
A. Vogel AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bioforce AG
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eugen Riedi, MD
Role: PRINCIPAL_INVESTIGATOR
independent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Eugen Riedi
Chur, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
920136
Identifier Type: -
Identifier Source: org_study_id